OncRef

Clinical Trial: NCT05306340

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Genentech, Inc.
Information Provided By:Genentech, Inc.
Last Update Posted:2026-11-03

Study Overview

Brief Summary

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.

Official Title

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Conditions

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Intervention / Treatment

  • Drug: Giredestrant
  • Drug: Exemestane
  • Drug: Fulvestrant
  • Drug: Tamoxifen
  • Drug: Everolimus
  • Drug: LHRH Agonist
  • Drug: Dexamethasone Mouth Rinse

Other Study ID Numbers

  • ML43171
  • 2022-000199-20
  • 2023-506821-12-00
  • 2023

Start Date (Actual)

2022-08-03

Primary Completion Date (Actual)

2025-07-16

Study Completion Date (Estimated)

2027-06-15

Enrollment (Actual)

373

Study Type

Interventional

Phase

Phase 3